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Summary 
The malignant, CD5 + B lymphocytes of B cell chronic lymphocytic leukemia (B-CLL) die by 
apoptosis in vitro. This is in contrast to the prolonged life span of the leukemic cells in vivo 
and likely reflects the lack of essential growth factors in the tissue culture medium. We found 
that interferon 3~ (IFN-3~) inhibits programmed cell death and promotes survival of B-CLL cells 
in culture. This effect may also be important in vivo: increased serum levels of IFN-% ranging 
from 60 to >2,200 pg/ml, were found in 7 of 10 B-CLL samples tested, whereas the sera of 
10 healthy individuals did not contain detectable levels of this cytokine (<20 pg/ml). High levels 
of IFN-'y message were detected in RNA from T cell-depleted B-CLL peripheral blood samples 
by Northern blot analysis. Synthesis of IFN-3' by B-CLL lymphocytes was confirmed by in situ 
hybridization and flow cytometry. The majority of B-CLL cells (74-82%) expressed detectable 
levels of IFN-~/mRNA, and CD19 + B-CLL cells were labeled with anti-IFN-3,  monoclonal 
antibodies. These results show that IFN-'y inhibits programmed cell death in B-CLL cells and 
suggest that the malignant cells are able to synthesize this cytokine. By delaying apoptosis, IFN-~/ 
may extend the life span of the malignant cells and thereby contribute to their clonal accumulation. 
B  cell chronic lymphocytic leukemia (B-CLL) is character- 
ized by the slow and progressive accumulation of mono- 
donal, apparently  mature, CD5 + B lymphocytes  (1). The 
majority of circulating cells appear to be nondividing (2), 
and it has been suggested that a prolonged life span is mainly 
responsible for the accumulation of the leukemic cells (3). 
The absence of growth factors induces programmed cell 
death (apoptosis) in many cultured lymphohemopoietic cells. 
For example, growth factor-dependent cell lines and IL-2- 
dependent T lymphocytes initiate apoptosis after the appro- 
priate factors are withdrawn (4). When B-CLL samples are 
placed in culture, apoptosis occurs despite the presence of FCS 
in the tissue culture medium (5). Thus, apoptosis in cultured 
B-CLL cells may be triggered by the absence of a survival- 
promoting factor (or factors), present in vivo. The identifi- 
cation of such a molecule would not only increase our un- 
derstanding of pathogenesis in B-CLL, but might ultimately 
allow the development  of targeted  treatment. 
The CD5 + B cells that accumulate in B-CLL are rare in 
normal periperal blood (6). Whether normal or malignant 
human  CD5 +  B  cells respond  to  different  survival  or 
proliferation  signals  than  CD5-  B  cells is not yet dear. 
However, it has been shown that administration of IFN-3r 
shortens  the life span of the Fa hybrids  of New Zealand 
Black and New Zealand White mice (7) in which elevated 
levels of Ly-1  + B  cells, the murine equivalent  of human 
CD5 + B lymphocytes,  parallel the progression  of autoim- 
mune disease (6). Furthermore, injection of anti-IFN-3( anti- 
bodies significantly prolonged survival of the animals com- 
pared with untreated controls (7). 
These observations prompted us to examine the effects of 
IFN-3' on CD5 + B cells from patients  with B-CLL and to 
test the hypothesis that IFN-'y acts as a survival signal for 
these cells. This study provides evidence that IFN-'y inhibits 
programmed cell death in cultured B-CLL cells. We also 
present  data suggesting that IFN-3, may promote survival 
of B-CLL cells in vivo and that this cytokine is produced 
by the malignant cells themselves. 
Materials and Methods 
Samples.  Sterile  heparinized  peripheral  blood samples  were ob- 
tained from nine B-CLL patients and five  normal  individuals.  Serum 
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volunteers. Diagnosis of B-CLL was unequivocal according to clln- 
ical, morphologic, and immunologic criteria. None of the patients 
had received chemotherapy for at least 3 mo before the samples 
were drawn; serum samples were obtained from previously  untreated 
patients.  Fresh  and  cryopreserved  B.-CLL cdls  were  studied. 
Mononuclear ceils were isohted by two consecutive centrifugations 
on Ficoll-Hypaque density gradient (Lymphoprep; Nyegard, Oslo, 
Norway). B-CLL cells were further purified by depletion of mono- 
cytes by adherence to plastic tissue culture dishes(Nunc, Koskilde, 
Denmark).  For 1LNA analysis T calls were depleted (see below). 
B-CLL cell preparations  contained  ;;)90% CD19 + cells, 990% 
CD5 + cells, <5% CD2 + cells, and <1% CD14 + cells as assessed 
by staining with mAbs (AMAC, Inc., Westbrook, ME). Trypan 
blue excluding cells exceeded 95% in all cases studied. 
Cell Culture.  Separated  cells were cultured at a concentration 
of 1-2  x  106 cells/m1 RPMI 1640 supplemented with 10% heat- 
inactivated  FCS (batch 9MO57; Whittaker M.A.  Bioproducts, 
Walkersville, MD) and antibiotics.  The  following  recombinant 
cytokines were used at the final concentrations indicated: 100 U/ml 
IL-1 (Hoffmann-La Koche, Inc.,  Nutley,  NJ),  1,000 U/ml Ib2, 
(Cetus Corp., EmeryviUe, CA), 50 ng/ml IL-6 ISandoz Pharmaceu- 
ticals, East Hanover, NJ), 25 ng/ml IL-7 (R. & D  systems, Min- 
neapolis, MN), and  100 U/ml IFN-3, (sp act,  3  x  107 U/mg; 
Genentech, South San Francisco, CA). 12-O-tetradecanoylphorbol 
13-acetate (TPA; Sigma Chemical Co., St.Louis,'MO), which has 
been shown to prevent apoptosis of B-CLL calls (8), was used at 
a final concentration of 2  x  10 -s M. After initial titration,  IFN-3, 
was added daily at a final concentration  of 100 U/m1. 
Measurement ofSohble IFN-'r.  Serum samples were analyzed 
for the presence of IFN-"/by an ELISA (Bethesda Research Labora- 
tories,  Gaithersburg,  MD),  with  an  IFN-y detection  limit  of 
20 pg/ml. 
Analysis ofApoptosis.  Apoptosis was studied by light micros- 
copy, by DNA gel electrophoresis, and flow cytometry. Cytocen- 
trifuge preparations were stained with Wright-Giemsa  for light 
microscopy analysis of apoptosis. 2  x  10" cells were assayed for 
DNA fragmentation  after 16-24 h of culture as described (9). For 
flow cytometric analysis, 10" cells were stained with CD19 mAbs 
(AMAC, Inc.) and analyzed by flow cytomet~ on day 0, as well 
as after 3, 5, and 7 d in culture  as detailed dsewhere (9). 
Determination of Cell Numbers.  Trypan  blue-exduding cells of 
three  aliquots  of  every  sample  were  counted  in  a  standard 
hemocytometer.  A previously published technique was used for 
counting CD19 + ceils from samples harvested on days 0, 1, 3, 5, 
7, and 9 of culture by flow cytometry (9). 
Ki-67 Staining.  Cytospin preparations of cells from four patients 
cultured  with and without the addition of 100 U/m1 IFN-3' for 
3 and 7 d were fixed with methanol for 30 min at 4~  and stained 
with Ki-67 antibody (Dako Corp., Carpinteria,  CA) followed by 
incubation with FITC-labeled goat anti-mouse (GAM) Ig (Jackson 
Immunoresearch Laboratories, West Grove, PA). Slides were ex- 
amined by fluorescence microscopy. 
RNA Analysis.  Cryopreserved B-CLL cells from thr~ patients, 
T cell depleted by rosetting with sheep red blood cells (<2% CD2 
cells), were used for Northern analysis of IFN-~/mlLNA. Cells 
were cultured for 6 h in the presence,  or absence of 2  x  10- s M 
TPA and 7.5  x  10 -7 M calcium ionophore A23187 (Sigma Chem- 
ical Co.). 20 tzg KNA was separated on 1% agarose/6%  formalde- 
hyde gels, transferred to nitrocellulose, and the filter hybridized 
to a 32p-labded 1.0-kb PstI IFN-3" eDNA fragment  (gift of Dr. 
G. P,  icca, Rorer Bioteehnology, King of Prussia, PA) as described 
(10). The stripped filter was hybridized to a 2.0-kb PstI chicken 
~-actin  probe. For in situ hybridization  analysis, CD2 + cells of 
two patients were further depleted with CD2-coated magnetic beads 
following the manufacturer's recommendations (Dynal, Great Neck, 
NY): cell preparations contained >99.5% CD19 + cells after sepa- 
ration.  After stimulation  (see above), cytocentrifuge preparations 
were fiaz~l in 4% paraformaldehyde and hybridized to a 3sS-hbeled 
complementary IFN-3, KNA probe comprising positions 220-520 
of the haman IFN-3, eDNA as described (11). Sense ILNA tran- 
scripts served as negative controls. 
Detection oflntraceUular IFN-7.  Cells from five patients were 
cultured  in  the  presence  of TPA  and  calcium ionophore  for 
4-24 h. After surface staining with CD19 mAb of IgM subclass 
(done AB1), 10' cells were incubated with GAM IsM Abs con- 
jugated to PE (Jackson Immunoresearch Laboratories). Cells were 
then fixed for 16 h with 0.5% paraformaldehyde at 4~  and per- 
meabilized with 0.2% Twr  20 (Bio-Rad Laboratories, Richmond, 
CA) in PBS as described (12). After permeabilization  calls were 
incubated with carefully titrated neutralizing  anti-human IFN-3, 
mAbs of IgG1 subchss DC10 or GZ-4 (Boehringer Mannheim Bio- 
chemicals, Indianapolis, IN) for 10 rain at room temperature fol- 
lowed by one wash in PBS supplemented with 0.2% Tween 20 
and one wash in PBS supplemented with 0.2% albumin and 0.2% 
sodium azide (PBSA). Isotype-matched unreactive Abs were used 
as control.  Bound antibodies were visualized by incubation with 
FITC-labeled GAM IgG as above followed by fixation with 0.5 
ml 0.5% paraformaldehyde. 
Results 
IFN-7 Inhibits Apoptosis of Cultured B-CLL  Cells.  Un- 
treated B=CLL cells rapidly initiated apoptosis when placed 
in culture,  as previously described (5). After 16 h,  5-20% 
of ceils showed morphologic evidence of apoptosis such as 
nuclear fragmentation  and loss of cell volume (Fig.  1).  At 
the same time degradation  of DNA into fragments of 180 
bp and multiples was seen (Fig.  2). The forward and side- 
ward light scattering changes of apoptotic cells (9; data not 
shown) also became apparent when cultured B-CLL ceils were 
analyzed by flow cytometry. By day 5, only 56 _+ 6.1% (mean 
_+  SD) of the original  cell number was recovered. 
Addition of rlFN-3' to the tissue culture medium inhibited 
apoptosis (Figs. 1 and 2). In the lamence of IFN-y (100 U/ml), 
94  _+ 3.6% (mean  +  SD) of the CD19 + lymphocytes orig- 
inally plated were recovered on day 5.  IFN=qr was eff~tive 
at a concentration  of 25 U/m1 with  maximum  inhibition 
achieved  in  the  range  of 100-1,000  U/ml  (equivalent  to 
'~3-30 ng/ml recombinant protein) and the effects of IFN-3~ 
persisted for 7-9 d  (data not shown). 
Although IFN-qt prevented apoptosis, there was no evi- 
dence of call proliferation as determined by staining with Ki- 
67, an antibody that recognizes a ceU cycle-related antigen 
(13): <0.1% lymphocytes of four patients were labeled after 
3  and 7 d of culture in the presence of 100 U/ml IFN-% 
confirming previous reports (14). In contrast to IFN-% IL-1, 
Ib2, IL-6, and IL-7 failed to prevent DNA degradation and 
to support  survival (Fig.  2). 
B-CLL Cells Synthesize IFN-'r.  Next, we measured IFN-y 
levels in sera from 10 B-CLL patients and in 10 healthy indi- 
viduals.  As illustrated  in Fig.  3,  7 of 10 B=CLL sera con- 
tained IFN-3'. The amount of IFN-3' detected ranged from 
214  IFN-y Inhibits Apoptotic CeU Death of Leukemic B Cells Figure 1.  Apoptotic cell death of B-CLL cells is prevented  by IFN-% B-CLL cells were cultured for 16 h and cytocentrifuge preparations stained 
with Wright-Giemsa. (a) B-CLL cells treated with  100 U/ml rIFN-% (b) Apoptotic B-CLL lymphocytes in untreated culture. 
60 to >2,200 pg/ml. IFN-3' levels in the sera tested did not 
correlate with the white blood cell count. Five samples with 
detectable IFN-~ were from patients at stage 0 of the disease 
according to Rai et al. (15), whereas the other two positive 
samples were from patients at stages I and II, respectively. 
The remaining three patients with no detectable IFN-'), levels 
in the serum were at stage 0. None of the patients had din- 
ical signs of infection. No IFN-'),  (<20 pg/ml) was detect- 
able in sera from 10 healthy volunteers. 
IFN-3,  synthesis by B-CLL cells in vitro was studied at 
the RNA and protein level. For Northern analysis, three sam- 
ples with <2%  CD2 + lymphocytes were selected. B-CLL 
cells produced IFN-3' mRNA rapidly and at high levels upon 
activation with TPA and calcium ionophore (Fig. 4). By in 
situ hybridization using antisense RNA probes, the majority 
of B-CLL cells in two cases tested (74 and 82%) were found 
to synthesize IFN-3' transcripts (Fig.  5). 
Using double-color immunofluorescence  and flow cytom- 
etry, we found that in normal peripheral blood samples acti- 
Figure 2.  IFNw inhibits DNA fragmentation in cultured B-CLL cells. 
B-CLL cells were lysed after 16 h in culture in the absence  (control)  or 
presence of IFN-% I1.-1,  ID2, IL-6, II-7, and TPA as described in Materials 
and Methods. (.4) Fragmented DNA. (B) Pellets containing intact DNA 
and cell debris, serving as control for equal loading, 
tFN-v [pg/mi] I 
=  looo  J-JIL~  ,.T||  .| 
~  B||  l=,..._...=. 
1  2  3  4  5  6  7  8  9  10  controls 
Patients  n  =  10 
Figure 3.  B-CLL sera contain IFN-% Serum samples from 10 B-CLL 
patients and 10 healthy volunteers  were analyzed by ELISA for the pres- 
ence of IFN-% Lev*ls of IFN-'y were heterogeneous in patients ranging 
from 60 to >2,200 pg/ml. No IFN-3, was detectable in sen of healthy 
volunteers. 
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cells was analyzed for expression of IFN-'y  message after stimulation with 
TPA and calcium ionophore for 6 h. CD2  + cells represented <2% of each 
sample tested. Filters were rehybridized with B-actin, indicating the rela- 
tive amount of KNA loaded. 
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Figure 6.  IFN-"/protein is synthesized  by stimulated B-CLL ~ls. B-CLL 
lyrnphocytes and PBMC were stimulated  with TPA and calcium iono- 
phore for 24 h and stained simultaneously  with CD19 and anti-IFN-3~ 
mAbs as described in Materials and Methods. Pmparatiom were analyzed 
by flow cytometry.  (,4)  PBL:  8%  CD19-  cells are labeled with anti- 
IFN-  V mAb.  (B) B-CLL cells: 2.5%  of the lymphocytes  are CD19*/ 
IFN-3,+; 0.5% CD19- cells were also labeled with anti-IFN-3, mAb. A 
representative experiment  is shown. 
vated with TPA and calcium ionophore, IFN-'y was exclu- 
sively synthesized  by  6-8%  CD19-  cells, presumably  T 
lymphocytes (16) (Fig. 6). By contrast, in B-CLL samples 
most IFN-'y-producing cells were CD19 + B lymphocytes: 
between 1 and 5%  CD19 + B-CLL cells synthesized  high 
levels of this cytokine and a small proportion (g0.5%) of 
CD19-  lymphocytes were also labeled by the anti-IFN-y 
mAb (Fig. 6). IFN-'y synthesis was observed 6 h after activa- 
tion, with maximum levels detectable  after 24 h. 
Discussion 
Alterations  in the mechanisms leading to cell death may 
play an important role in the pathogenesis of cancer. Devia- 
tion from a programmed death mechanism could result in 
donal accumulation of cells normally present at very low levels 
or representing a transitory cell type. Programmed cell death 
appears to be regulated by cytokines acting as survival signals 
(17). Thus, autocrine secretion or aberrant levels of certain 
cytokines could be responsible for delayed apoptosis and ex- 
tended survival of malignant cells (18). 
Our studies showed that IFN-~/can promote survival in 
malignant cells from patients with B-CLL. The potential in 
vivo relevance of this phenomenon is suggested by the detec- 
tion of IFN-~/in the serum of 7 of 10 B-CLL cases tested. 
At the concentrations observed in vivo, this cytokine could 
indeed be responsible for prolonging the life span of the malig- 
nant cells. 
IFN-3~ may act directly on B-CLL cells or through the 
induction of, or in conjunction with, other factors. For ex- 
ample, it has been recently reported that IFN-'y increases ex- 
pression of the CD23 antigen on the surface of B-CLL cells, 
and elevated levels of the soluble form of CD23, which pre- 
vents apoptosis of germinal center B cells (19), are also found 
Figure 5.  In situ hybridization analysis of 
IFN-3' synthesis: the majority of B-CLL (74 
and 82%) cells synthesize IFN~ transcripts. 
Samples contained >99.5% CD19 + B lym- 
phocytes. (A) B-CLL cells probed with IFN-'y 
sense ~pts  (negative  control). (B) B-CLL 
cells hybridized  with a complementary IFN-'y 
RNA probe. 
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proliferation of B-CLL cells, as cell numbers in IFN-7-treated 
samples remained constant and we and others (14) did not 
find evidence for cell division of the leukemic cells after IFN-7 
treatment.  In vivo proliferation of B-CLL cells may be in- 
duced by other lymphokines  such as TNF  (21). 
IFN-7 appears  to be synthesized by the malignant,  CD5 + 
B cells of patients with CLL. We were able to detect IFN-7 
mRNA by Northern blot analysis and in situ hybridization 
in the majority of these malignant B lymphocytes. Further- 
more,  analysis  of IFN-7  protein  synthesis  using  double- 
color immunofluorescence and flow cytometry showed that 
CD19 + B=CLL  lymphocytes contained  high  levels  of this 
cytokine, suggesting an autocrine production of IFN-7 by 
the malignant  B-CLL cells. 
In conclusion, our results indicate that IFN-7 is a survival 
promoting factor for B-CLL cells and suggest that the malig- 
nant  cells  may contribute to the synthesis of the survival- 
promoting cytokin~ Our observations may provide a rationale 
for novel therapeutic strategies based on inhibition of IFN-7 
effects on B-CLL cells. 
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